Buradasınız

Anasayfa » Content

Ergenlikte venlafaksin kullanımına bağlı kesilme sendromu: bir olgu sunumu

Withdrawal syndrome due to venlafaxine in adolescence: a case report

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Venlafaxine is a non-tricyclic antidepressant which inhibits the re-uptake of serotonin, noradrenalin and dopamine. Venlafaxine is reportedly effective in the treatment of depression, anxiety, and attention deficit and hyperactivity disorder in childhood and adolescence. Symptoms of withdrawal have been reported in many of the psychotropic medications. In this article, a withdrawal syndrome developing after the discontinuation of venlafaxine treatment in a 16-year-old adolescent, who was diagnosed to have major depression is reported. Symptoms of withdrawal developed only after the cessation of venlafaxine treatment in the present case who were treated with sertraline and venlafaxine, respectively in the treatment process. Adolescents and their parents should be informed about not ceasing the antidepressant treatment abruptly in order to avoid the withdrawal syndromes due to antidepressant drugs.
Bookmark/Search this post with
Abstract (Original Language): 
Venlafaksin serotonin, noradrenalin ve dopamin geri alımını engelleyen trisiklik yapıda olmayan bir antidepresandır. Venlafaksinin çocuk ve ergenlerde depresyon, anksiyete ve dikkat eksikliği hiperaktivite bozukluğu tedavisinde etkin olabileceği belirtilmektedir. Kesilme bulguları çoğu psikotrop ilaç ile tanımlanmıştır. Bu yazıda majör depresyon tanısı konan 16 yaşında bir ergen olguda venlafaksin tedavisinin sonlandırılması ile ortaya çıkan bir kesilme sendromu tablosu sunulmuştur. Tedavi sürecinde sırasıyla sertralin ve venlafaksin kullanmış olan olgunun sadece venlafaksin tedavisinin sonlandırılma sürecinde kesilme bulgularının ortaya çıktığı saptanmıştır. Antidepresan ilaçlara bağlı kesilme sendromlarına yol açmamak için, özellikle ergen hastalar ve ailelerinin antidepresan tedaviyi ani olarak kesmemeleri gerektiği hakkında bilgilendirilmesi gereklidir.
FULL TEXT (PDF): 
PDF icon arastirmax-ergenlikte-venlafaksin-kullanimina-bagli-kesilme-sendromu-bir-olgu-sunumu.pdf
  • 1
41-43
  • Turkish

REFERENCES

References: 

Kaynaklar
1. Holliday SM, Benfield P. Venlafaxine: a review of its
pharmacology and therapeutic potential in depression.
Drugs 1995; 49: 280-294.
2. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y.
Venlafaxine ER for the treatment of pediatric subjects
with depression: results of two placebo-controlled trials.
J Am Acad Child Adolesc Psychiatry 2007; 46: 479-488.
3. Rynn MA, Riddle MA, Yeung PP, Kunz NR. Efficacy
and safety of extended-release venlafaxine in the
treatment of generalized anxiety disorder in children
and adolescents: two placebo-controlled trials. Am J
Psychiatry 2007; 164: 290-300.
4. Findling RL, Greenhill LL, McNamara NK, et al.
Venlafaxine in the treatment of children and adolescents
with attention-deficit/hyperactivity disorder. J Child
Adolesc Psychopharmacol 2007; 17: 433-445.
5. Effexor XR (Venlafaxine Hydrochloride) patient
information. http://www.rxlist.com/cgi/generic/
venlafax_pi.htm (Son erişim tarihi: 23.09.2008).
6. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake
inhibitor withdrawal. J Clin Psychopharmacol 1996;
16: 356-362.
7. Fava M, Mulroy R, Alpert J, et al. Emergence of adverse
effects following discontinuation of treatment with
extended-release venlafaxine. Am J Psychiatry 1997;
154: 1760-1762.
8. Haddad P. The SSRI discontinuation syndrome. J
Psychopharmacol 1998; 12: 305-313.
9. Haddad PM. Antidepressant discontinuation syndromes:
clinical relevance, prevention and management. Drug
Safety 2001; 24: 183-197.
10. Diler RS, Avci A. Selective serotonin reuptake inhibitor
discontinuation syndrome in children: six case reports.
Curr Ther Res Clin Exp 2002; 63: 188-197.
11. Diler RS, Tamam L, Avci A. Withdrawal symptoms
associated with paroxetine discontinuation in a 9-year
old boy. J Clin Psychopharmacol 2000; 20: 586-587.
12. Tamam L, Ozpoyraz N. Selective serotonin reuptake
inhibitor discontinuation syndrome: a review. Adv
Ther 2002; 19: 17-26.

Thank you for copying data from http://www.arastirmax.com